Overview

ZIMMER BIOMET HOLDINGS, INC.

ZBHNYSEHealth CareOrthopedic, Prosthetic & Surgical Appliances & SuppliesCIK 0001136869S&P 500

Latest 10-K: FY2025, filed Feb 20, 2026 · Open the 10-K (Inline XBRL) ↗

Revenue: $8.23B; 7.2%up from FY2024; TotalRevenue
Operating income: $1.10B; 14.6%down from FY2024; OperatingIncome
Net income: $0.71B; 22.0%down from FY2024; NetIncome
Diluted EPS: $3.55; 19.9%down from FY2024; EPSDiluted
Net margin: 8.6%; 3.2 ppdown from FY2024
S&P 500 median 12.8%
Free cash flow: $1.47B; 13.7%up from FY2024

FY2025 versus the prior fiscal year.

At a glance

ZIMMER BIOMET HOLDINGS, INC. reported revenue of $8.23B for fiscal 2025, up 7.2% from fiscal 2024.

Operating margin was 13.3% and net margin was 8.6%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

Diluted EPS was $3.55, down 19.9% from the prior year.

Revenue grew faster than the median S&P 500 member in 2 of the last 5 fiscal years.

Over the past 12 months, insiders reported 6 open-market sales totalling $1.6M on Form 4.

1,194 institutions reported holding ZIMMER BIOMET HOLDINGS, INC. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Dodge & Cox's.

Data as of Oct 18, 2026 · Sources: SEC EDGAR 10-K, Form 4, 13F

Quick answers

What was ZIMMER BIOMET HOLDINGS, INC.'s revenue in fiscal 2025?: ZIMMER BIOMET HOLDINGS, INC. reported revenue of $8.23B for fiscal 2025, up 7.2% from fiscal 2024.
What is ZIMMER BIOMET HOLDINGS, INC.'s net margin?: Operating margin was 13.3% and net margin was 8.6%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.
What is ZIMMER BIOMET HOLDINGS, INC.'s diluted EPS?: Diluted EPS was $3.55, down 19.9% from the prior year.
Are ZIMMER BIOMET HOLDINGS, INC. insiders buying or selling shares?: Over the past 12 months, insiders reported 6 open-market sales totalling $1.6M on Form 4.
Which institutions hold ZIMMER BIOMET HOLDINGS, INC. stock?: 1,194 institutions reported holding ZIMMER BIOMET HOLDINGS, INC. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Dodge & Cox's.

Data as of Oct 18, 2026 · Sources: SEC EDGAR 10-K

Data as filed with the SEC, provided for information only — not investment advice.

Every figure Valuein returns traces to its SEC filing. How we build this data →

Earnings power

Five fiscal years of revenue and earnings, each margin on revenue, and the change from the prior year — compared with the typical S&P 500 company.

Revenue

TotalRevenue

$8.23B

4.8%FY2021→FY2025 CAGR

Grew faster than the S&P 500 median in 2 of 5 years

Gross profit

GrossProfit

$5.74B

4.2%FY2021→FY2025 CAGR

Operating income

OperatingIncome

$1.10B

6.3%FY2021→FY2025 CAGR

Net income

NetIncome

$0.71B

15.1%FY2021→FY2025 CAGR

Grew faster than the S&P 500 median in 1 of 4 years

EPS (diluted)

EPSDiluted

$3.55

16.8%FY2021→FY2025 CAGR

Grew faster than the S&P 500 median in 1 of 4 years

Year by year vs S&P 500

Revenue growth, each year on its ownZBHS&P 500 median

Revenue growth, each year on its own
Fiscal year	ZBH	S&P 500 median
2021	11.4%	14.8%
2022	1.6%	9.7%
2023	6.5%	4.9%
2024	3.8%	4.6%
2025	7.2%	6.4%

Net margin, each year on its ownZBHS&P 500 median

Net margin, each year on its own
Fiscal year	ZBH	S&P 500 median
2021	5.9%	13.5%
2022	3.3%	12.2%
2023	13.8%	12.7%
2024	11.8%	12.5%
2025	8.6%	12.8%

Each year stands alone, nothing is compounded. “—” means the figure is not available.

Annual earnings, change versus the prior year and margin on revenue, with the S&P 500 median. USD, newest fiscal year first.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021
RevenueTotalRevenue	$8.23B	$7.68B	$7.39B	$6.94B	$6.83B
Change vs prior year	7.2%up	3.8%up	6.5%up	1.6%up	11.4%up
S&P 500 median change	6.4%	4.6%	4.9%	9.7%	14.8%
Gross profitGrossProfit	$5.74B	$5.49B	$5.31B	$4.92B	$4.87B
Change vs prior year	4.6%up	3.3%up	7.9%up	1.1%up	13.1%up
Margin	69.7%	71.5%	71.8%	70.9%	71.3%
Compared with the index	S&P 500 median: not published
Operating incomeOperatingIncome	$1.10B	$1.29B	$1.28B	$0.70B	$0.86B
Change vs prior year	14.6%down	0.6%up	83.5%up	19.1%down	935.3%up
Margin	13.3%	16.7%	17.3%	10.0%	12.6%
Compared with the index	S&P 500 median: not published
Net incomeNetIncome	$0.71B	$0.90B	$1.02B	$0.23B	$0.40B
Change vs prior year	22.0%down	11.7%down	342.5%up	42.4%down	n/m
Margin	8.6%	11.8%	13.8%	3.3%	5.9%
S&P 500 median change	4.7%	5.7%	1.7%	1.8%	—
S&P 500 median margin	12.8%	12.5%	12.7%	12.2%	13.5%
EPS (basic)	$3.56	$4.45	$4.91	$1.10	$1.93
Change vs prior year	20.0%down	9.4%down	346.4%up	43.0%down	n/m
S&P 500 median change	5.6%	6.4%	1.2%	0.0%	—
EPS (diluted)EPSDiluted	$3.55	$4.43	$4.88	$1.10	$1.91
Change vs prior year	19.9%down	9.2%down	343.6%up	42.4%down	n/m
S&P 500 median change	6.1%	7.9%	1.3%	1.2%	—

n/m: not meaningful — the prior year was zero or negative. “—” means the figure is not available.

S&P 500 median = median of the companies in the index on Dec 31 of each fiscal year, from their own 10-K filings; a change counts only companies whose prior year was positive. Published only where at least 400 members report the line item. Updated 2026-10-18. This compares reported earnings, not share-price returns. Methodology

Financial statements

Annual figures from the 10-K, most recent fiscal year first.

Income Statement

5 annual periods

Income Statement, annual, most recent fiscal year first
Metric	FY25Dec '25	FY24Dec '24	FY23Dec '23	FY22Dec '22	FY21Dec '21
RevenueTotalRevenue	$8.23B	$7.68B	$7.39B	$6.94B	$6.83B
Gross ProfitGrossProfit	$5.74B	$5.49B	$5.31B	$4.92B	$4.87B
Operating IncomeOperatingIncome	$1.10B	$1.29B	$1.28B	$0.70B	$0.86B
Net IncomeNetIncome	$0.71B	$0.90B	$1.02B	$0.23B	$0.40B
EPS (Diluted)EPSDiluted	$3.55	$4.43	$4.88	$1.10	$1.91

Balance Sheet

5 annual periods

Balance Sheet, annual, most recent fiscal year first
Metric	FY25Dec '25	FY24Dec '24	FY23Dec '23	FY22Dec '22	FY21Dec '21
Total AssetsTotalAssets	$23.09B	$21.37B	$21.50B	$21.07B	$23.46B
Total LiabilitiesTotalLiabilities	$10.39B	$8.89B	$9.01B	$9.04B	$10.79B
Stockholders' EquityStockholdersEquity	$12.71B	$12.48B	$12.49B	$12.03B	$12.67B
Cash & EquivalentsCashAndEquivalents	$0.59B	$0.53B	$0.42B	$0.38B	$0.38B
Total DebtTotalDebt	—	—	—	—	—

Cash Flow Statement

5 annual periods

Cash Flow Statement, annual, most recent fiscal year first
Metric	FY25Dec '25	FY24Dec '24	FY23Dec '23	FY22Dec '22	FY21Dec '21
Operating Cash FlowOperatingCashFlow	$1.70B	$1.50B	$1.58B	—	$1.50B
Capital ExpendituresCAPEX	$0.22B	$0.20B	$0.29B	$0.19B	$0.14B
Free Cash Flow	$1.47B	$1.30B	$1.29B	—	$1.36B

Ratios & Valuation

5 annual periods

Ratios & Valuation, annual, most recent fiscal year first
Metric	FY25Dec '25	FY24Dec '24	FY23Dec '23	FY22Dec '22	FY21Dec '21
Gross Margin	69.7%	71.5%	71.8%	70.9%	71.3%
Operating Margin	13.3%	16.7%	17.3%	10.0%	12.6%
Net Margin	8.6%	11.8%	13.8%	3.3%	5.9%
Return on Equity	5.6%	7.2%	8.4%	1.9%	3.2%
Return on Assets	3.2%	4.2%	4.8%	1.0%	1.7%
Debt / Equity	0.59×	0.50×	0.46×	0.47×	0.56×

Cash & capital allocation

Where the cash went in FY2025, from the 10-K cash flow statement.

Operating cash flow: $1.70B
Capex: $224.50M
Free cash flow: $1.47B
R&D: $458.50M
Buybacks: $487.00M
Dividends: $190.30M
Debt repaid: —
Debt issued: —
Net debt change: —

Uses of operating cash flow, FY2025

Buybacks28.7%
Dividends11.2%
Capex13.2%

Each use is shown against operating cash flow on its own; the uses overlap.

Free cash flow by year

FY21$1.36B
FY22—
FY23$1.29B
FY24$1.30B
FY25$1.47B

Buybacks by year

FY21—
FY22$126.40M
FY23$692.20M
FY24$868.00M
FY25$487.00M

Smart money

Who is trading and holding ZIMMER BIOMET HOLDINGS, INC., from Form 4, 13F and 13D/13G filings.

Insiders

Insider sentiment · last 365 days

Buys: 0
Sales: 6
Value sold: $1.6M
Shares sold: 17,341

Score −100 on a fixed −100 to +100 scale · role-weighted: CEO and CFO count 3×

Cluster: 3 or more insiders traded within 30 days.

Largest sellers

Kevin R. Thornal1 transaction
Sang Yi3 transactions
Chad F. Phipps1 transaction
Lori Winkler1 transaction

Insider activity · past 12 months

Buys

0 insiders

Sales

4 insiders · $1.6M

Purchases 0% of valueSales 100% of value

Latest open-market insider trades from Form 4
Date	Insider	Role	Type	Shares	Price	Value	Filing
Sep 11, 2026	Thornal Kevin R	Grp Pres-Global Business	Sale	5,691	$92.95	$528,978	View filing on SEC EDGAR
Sep 4, 2026	Phipps Chad F	See remarks below.	Sale	3,000	$98.35	$295,050	View filing on SEC EDGAR
May 29, 2026	Yi Sang	Group President, Asia Pacific	Sale	4,200	$82.64	$347,088	View filing on SEC EDGAR
May 29, 2026	Yi Sang	Group President, Asia Pacific	Sale	800	$82.66	$66,128	View filing on SEC EDGAR
Mar 12, 2026	Winkler Lori	SVP and CHRO	Sale	2,650	$94.66	$250,849	View filing on SEC EDGAR

Open-market purchases (code P) and sales (code S) only. Grants, option exercises and tax withholding are excluded. Sales may be made under pre-arranged Rule 10b5-1 plans.

Ownership

Largest institutional holders · 13F, quarter ended Jun 30, 2026

1,194 institutions reported positions.

Top institutional holders from 13F filings
Holder	Shares	Value	Filing
Dodge & Cox	24,124,735	$2.1B	View filing on SEC EDGAR
Vanguard Capital Management	12,634,937	$1.1B	View filing on SEC EDGAR
HARRIS ASSOCIATES L P	12,336,314	$1.1B	View filing on SEC EDGAR
Capital International Investors	12,183,614	$1.0B	View filing on SEC EDGAR
STATE STREET CORP	8,877,171	$766.3M	View filing on SEC EDGAR

13F filings are due 45 days after quarter end, so this shows the latest fully reported quarter. Amended filings are counted once.

Blockholders, 5% and over · SC 13D / 13G

Latest 13D and 13G filing per holder of 5% or more
Holder	Stake	Form	Filed	Filing
Dodge & Cox	12.5%	SC 13G/A	Aug 14, 2026	View filing on SEC EDGAR
IDENTIFICATION NO. OF ABOVE PERSON	8.4%	SC 13G/A	Nov 13, 2024	View filing on SEC EDGAR
BlackRock, Inc.	7.8%	SC 13G/A	Apr 17, 2025	View filing on SEC EDGAR
Vanguard Capital Management	7.54%	SC 13G	Apr 30, 2026	View filing on SEC EDGAR
Capital International Investors	6.4%	SC 13G	Aug 12, 2026	View filing on SEC EDGAR
Harris Associates, Inc.	6.2%	SC 13G	Feb 17, 2026	View filing on SEC EDGAR

No filer switched from a passive 13G to an activist 13D in the last 365 days.

Latest filing per filer within three years; a later filing reporting 0% removes the filer.

Full history, every insider and 13F filer, 13D/G activist stakes, and webhooks are on Institutional.

See Institutional

Smart money

Showing the most recent 5 annual periods. Get longer history on the Pro plan, or the full history (1993–present) plus the smart-money dataset and webhooks on Institutional.

Restatement Radar

6 numbers ZIMMER BIOMET HOLDINGS, INC. later changed — same XBRL tag, both filings linked.

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2020
Major restatement
-$105.2M▲ 61.7%
was-$274.4M
Revised up in a 10-K.
No amendment filed
As reported · Feb 23, 2021 10-K · Feb 24, 2023us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2021
Major restatement
$499M▲ 19.3%
was$418.4M
Revised up in a 8-K.
No amendment filed
As reported · Feb 26, 2022 8-K · Aug 8, 2024us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q3 2021
Major restatement
$190.7M▲ 17.3%
was$162.6M
Revised up in a 10-Q.
No amendment filed
As reported · Nov 5, 2021 10-Q · Nov 3, 2022us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Revenue from Contract with Customer, Excluding Assessed Tax·Q1 2021
Major restatement
$1.6B▼ 13.3%
was$1.8B
Revised down in a 10-Q. Any P/S built on the original was 15.4% too low.
No amendment filed
As reported · May 5, 2021 10-Q · May 6, 2022us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Operating Income (Loss)·Q3 2021
Major restatement
$243M▲ 13.1%
was$214.9M
Revised up in a 10-Q.
No amendment filed
As reported · Nov 5, 2021 10-Q · Nov 3, 2022us-gaap:OperatingIncomeLoss
Revenue from Contract with Customer, Excluding Assessed Tax·Q2 2021
Major restatement
$1.8B▼ 13.0%
was$2B
Revised down in a 10-Q. Any P/S built on the original was 14.9% too low.
No amendment filed
As reported · Aug 4, 2021 10-Q · Aug 3, 2022us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax

ZBH is not the only one.

See every restatement we've found across the market — or get an alert the next time ZBH revises a number.

Restatement Radar Alert me

Restatements are detected by comparing every vintage of a fact across all of ZIMMER BIOMET HOLDINGS, INC.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows ZBH's most significant revisions, and a figure absent from it has not been certified as unrevised.

Peers, filings & research

Sector Peers

ALGN· Health Care

ALIGN TECHNOLOGY INC

EW· Health Care

Edwards Lifesciences Corp

ISRG· Health Care

INTUITIVE SURGICAL INC

Recent 10-K and 10-Q filings (SEC accession numbers)

Form	Accession ID	Report Date	Filing Date	Accepted At	Source
10-Q	0001193125-26-335044	Jun 30, 2026	Aug 5, 2026	Aug 6, 2026 00:06 UTC	EDGAR
10-Q	0001193125-26-201710	Mar 31, 2026	May 1, 2026	May 2, 2026 01:11 UTC	EDGAR
10-K	0001193125-26-059853	Dec 31, 2025	Feb 20, 2026	Feb 20, 2026 04:36 UTC	EDGAR
10-Q	0001193125-25-266884	Sep 30, 2025	Nov 5, 2025	Nov 6, 2025 02:06 UTC	EDGAR
10-Q	0000950170-25-104989	Jun 30, 2025	Aug 7, 2025	Aug 8, 2025 00:06 UTC	EDGAR
10-Q	0000950170-25-063509	Mar 31, 2025	May 5, 2025	May 6, 2025 00:00 UTC	EDGAR
10-K	0000950170-25-026604	Dec 31, 2024	Feb 25, 2025	Feb 26, 2025 02:01 UTC	EDGAR
10-Q	0000950170-24-118959	Sep 30, 2024	Oct 30, 2024	Oct 31, 2024 00:05 UTC	EDGAR
10-Q	0000950170-24-092746	Jun 30, 2024	Aug 7, 2024	Aug 8, 2024 00:05 UTC	EDGAR
10-Q	0000950170-24-052097	Mar 31, 2024	May 2, 2024	May 3, 2024 00:08 UTC	EDGAR
10-K	0000950170-24-019353	Dec 31, 2023	Feb 23, 2024	Feb 24, 2024 02:06 UTC	EDGAR
10-Q	0000950170-23-060232	Sep 30, 2023	Nov 7, 2023	Nov 8, 2023 02:05 UTC	EDGAR

Direct links to SEC EDGAR. ZBH has additional filings available on the SEC site.

Research Reports

No published research on ZBH yet.

Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on ZBH and publish the result to your public profile.

Browse the research catalog Generate one with your agent

The data behind this page

26 tables, schema 4.4.0, history 1993–present. Every figure above is a row you can query.

Fundamentals

Standardized financial facts, ratios and filings.

fact: 120.5Mrows
ratio: 5.3Mrows
filing: 2.35Mrows
entity: 19,888rows

292 standard concepts.

Smart money

Insider and institutional filings.

institutional_holding: 59.5Mrows
insider_transaction: 11.4Mrows
insider_filing: 5.2Mrows
insider_ownership: 1.33Mrows

78M+ smart-money rows in all.

One real fact row for ZIMMER BIOMET HOLDINGS, INC.

entity_id: 0001136869
standard_concept: OperatingCashFlow
fiscal_year: 2025
fiscal_period: FY
period_end: 2025-12-31
numeric_value: 1697100000
unit: USD
accession: 0001193125-26-059853
fact_id: ff6dd1315de3…494f10ce

Get the same data

bash

curl -H "Authorization: Bearer $VALUEIN_API_KEY" \  https://data.valuein.biz/v1/pro/fact/0001136869.parquet \  -o zbh.parquet

python

pip install valuein-sdkfrom valuein_sdk import ValueinClientwith ValueinClient() as client:    sql = "SELECT fiscal_year, numeric_value FROM fact WHERE entity_id = '0001136869' AND standard_concept = 'TotalRevenue' AND fiscal_period = 'FY'"    print(client.run_query(sql))

bash

https://mcp.valuein.biz/mcp Ask your agent:get_company_fundamentals ZBH   # CIK 0001136869

One token unlocks every channel. SDK docs · MCP docs

Cite this page

Data as of Oct 18, 2026. Canonical address: https://valuein.biz/data/ZBH

text

Valuein. (2026, October 18). ZIMMER BIOMET HOLDINGS, INC. (ZBH) financial statements, earnings power and smart-money summary [Data set]. Source: SEC EDGAR filings. https://valuein.biz/data/ZBH

text

@misc{valuein_zbh_2026,
  author = {{Valuein}},
  title = {ZIMMER BIOMET HOLDINGS, INC. (ZBH) financial statements, earnings power and smart-money summary},
  year = {2026},
  howpublished = {\url{https://valuein.biz/data/ZBH}},
  note = {Data as of 2026-10-18; source: SEC EDGAR filings}
}

Open 10-K in SEC Inline XBRL viewer

10-K filed Feb 20, 2026 · accession 0001193125-26-059853

Agents: every figure Valuein's tools return carries a fact_id that traces to its SEC filing.

point-in-time · survivorship-free · every number traceable to its SEC filing

View ZBH filings on SEC EDGAR

At a glance

02Earnings power

Revenue

Gross profit

Operating income

Net income

EPS (diluted)

Year by year vs S&P 500

03Financial statements

Income Statement

Balance Sheet

Cash Flow Statement

Ratios & Valuation

04Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

05Smart money

Insiders

Insider sentiment · last 365 days

Largest sellers

Insider activity · past 12 months

Ownership

Largest institutional holders · 13F, quarter ended Jun 30, 2026

Blockholders, 5% and over · SC 13D / 13G

Smart money

07Peers, filings & research

Sector Peers

Recent 10-K and 10-Q filings (SEC accession numbers)

Research Reports

08The data behind this page

Fundamentals

Smart money

One real fact row for ZIMMER BIOMET HOLDINGS, INC.

Get the same data

09Cite this page

04Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

05Smart money

Insiders

Insider sentiment · last 365 days

Largest sellers

Insider activity · past 12 months

Ownership

Largest institutional holders · 13F, quarter ended Jun 30, 2026

Blockholders, 5% and over · SC 13D / 13G

Sector Peers

Recent 10-K and 10-Q filings (SEC accession numbers)

08The data behind this page

Fundamentals

Smart money

One real fact row for ZIMMER BIOMET HOLDINGS, INC.

Get the same data

Earnings power

Financial statements

Cash & capital allocation

Smart money

Peers, filings & research

The data behind this page

Cite this page

Cash & capital allocation

Smart money

The data behind this page